文献速递消化系统肿瘤

林奇综合征家族中结直肠癌风险变异:回顾性队列研究

Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study.
PubMed 文献 · Lancet Oncol · 2021-06-07

BACKGROUND: Existing clinical practice guidelines for carriers of pathogenic variants of DNA mismatch repair genes (Lynch syndrome) are based on the mean age-specific cumulative risk (penetrance) of colorectal cancer for all carriers of pathogenic variants in the same gene.…

要点

  • 同一错配修复基因致病性变异携带者的结直肠癌终身风险存在广泛基因内变异。
  • MLH1和MSH2变异携带者风险变异尤为显著,7-56%终身风险<20%,9-44%>80%。
  • 未知家族风险因素显著修饰风险(p<0·0001),支持个体化风险评估。

核心结论

  • 未知家族风险因素显著修饰林奇综合征携带者的结直肠癌风险,导致同一基因内终身风险广泛变异,支持个体化精准预防和早期检测。

研究设计与样本

  • 国际错配修复联盟回顾性队列研究,纳入至少3名成员且至少1名确诊MLH1、MSH2、MSH6或PMS2致病/可能致病性变异携带者的家族,排除先证者为已知新发致病变异的家族。
  • 采用条件于确认方式的分离分析估计结直肠癌平均外显率,并建模未测量多基因因素以估计外显率变异。

主要发现

  • 三个大陆均发现未知家族风险因素修饰结直肠癌风险的强证据(p<0·0001)。
  • 同一基因或MSH2 c.942+3A>T变异携带者的结直肠癌风险存在广泛基因内变异,MLH1和MSH2变异携带者尤为显著。
  • MLH1和MSH2变异携带者中,7-56%结直肠癌外显率<20%,9-44%外显率>80%,仅10-19%外显率为40-60%,具体取决于基因、性别和大陆。

关键数值与推荐

  • MLH1和MSH2变异携带者中,7-56%结直肠癌外显率<20%,9-44%>80%,仅10-19%为40-60%。

临床怎么用

  • 对林奇综合征携带者进行结直肠癌风险评估时,应考虑家族风险修饰因素,而非仅依据基因平均外显率。
  • 研究结果支持基于个体化风险分层制定精准预防和早期检测策略。

局限性

  • 亚洲和南美洲家族数量不足,无法估计外显率;EPCAM变异携带者数据不足,未纳入分析。
  • 分析仅基于北美、欧洲和澳大拉西亚15国数据,其他地区外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Existing clinical practice guidelines for carriers of pathogenic variants of DNA mismatch repair genes (Lynch syndrome) are based on the mean age-specific cumulative risk (penetrance) of colorectal cancer for all carriers of pathogenic variants in the same gene. We aimed to estimate the variation in the penetrance of colorectal cancer between carriers of pathogenic variants in the same gene by sex and continent of residence. METHODS: In this retrospective cohort study, we sourced data from the International Mismatch Repair Consortium, which comprises 273 members from 122 research centres or clinics in 32 countries from six continents who are involved in Lynch syndrome research. Families with at least three members and at least one confirmed carrier of a pathogenic or likely pathogenic variant in a DNA mismatch repair gene (MLH1, MSH2, MSH6, or PMS2) were included. The families of probands with known de-novo pathogenic variants were excluded. Data were collected on the method of ascertainment of the family, sex, carrier status, cancer diagnoses, and ages at the time of pedigree collection and at last contact or death. We used a segregation analysis conditioned on ascertainment to estimate the mean penetrance of colorectal cancer and modelled unmeasured polygenic factors to estimate the variation in penetrance. The existence of unknown familial risk factors modifying colorectal cancer risk for Lynch syndrome carriers was tested by use of a Wald p value for the null hypothesis that the polygenic SD is zero. FINDINGS: 5585 families with Lynch syndrome from 22 countries were eligible for the analysis. Of these, there were insufficient numbers to estimate penetrance for Asia and South America, and for those with EPCAM variants. Therefore, we used data (collected between July 11, 2014, and Dec 31, 2018) from 5255 families (1829 MLH1, 2179 MSH2, 798 MSH6, and 449 PMS2), comprising 79 809 relatives, recruited in 15 countries in North America, Europe, and Australasia. There was strong evidence of the existence of unknown familial risk factors modifying colorectal cancer risk for Lynch syndrome carriers (p<0·0001 for each of the three three continents). These familial risk factors resulted in a wide within-gene variation in the risk of colorectal cancer for men and women from each continent who all carried pathogenic variants in the same gene or the MSH2 c.942+3A>T variant. The variation was especially prominent for MLH1 and MSH2 variant carriers, depending on gene, sex and continent, with 7-56% of carriers having a colorectal cancer penetrance of less than 20%, 9-44% having a penetrance of more than 80%, and only 10-19% having a penetrance of 40-60%. INTERPRETATION: Our study findings highlight the important role of risk modifiers, which could lead to personalised risk assessments for precision prevention and early detection of colorectal cancer for people with Lynch syndrome. FUNDING: National Health and Medical Research Council, Australia.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncol. 2021. PMID: 34111421. doi:10.1016/S1470-2045(21)00189-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。